×
About 28,328 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  9,681 results

Acute myeloid leukemia due to germline CEBPA mutation in a Syrian family.
https://doi.org/10.1002/mgg3.1854
Molecular Genetics & Genomic Medicine; Wafa A, Ali B et. al.

Jan 16th, 2022 - Familial cases of adult acute myeloid leukemia (AML) with germline-mutated CCAAT/enhancer-binding protein-α (CEBPA) gene are a rare entity classified in World Health Organization (WHO) classification 2016. Most families reported in the literature ...

Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow-up for im...
https://doi.org/10.1002/pbc.29525
Pediatric Blood & Cancer; Davis A, Stevens AM et. al.

Jan 15th, 2022 - Bloodstream infections (BSIs) cause morbidity and mortality in pediatric patients with leukemia. Antibiotic prophylaxis during periods of chemotherapy-induced neutropenia may reduce the incidence of BSIs. A levofloxacin prophylaxis guideline was i...

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT02914977

Jan 14th, 2022 - Disease relapse remains the primary challenge in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). There is no standard of care treatment option for relapsed acute leukemia, and investigational therapies are recom...

Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML ...
https://doi.org/10.1111/trf.16790
Transfusion Rubio-Azpeitia E, Pérez-Corral AM et. al.

Jan 14th, 2022 - Allogeneic stem cell transplantation is the treatment of choice for acute myeloid leukemia (AML) patients. Unmanipulated haploidentical transplantation (Haplo-HSCT) is commonly used for those AML patients who need a timely transplant and do not ha...

see more →

Guidelines  11 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Acute myeloid leukemia, version 2.2013.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

see more →

Drugs  29 results see all →

Clinicaltrials.gov  551 results

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT02914977

Jan 14th, 2022 - Disease relapse remains the primary challenge in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). There is no standard of care treatment option for relapsed acute leukemia, and investigational therapies are recom...

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leuk...
https://clinicaltrials.gov/ct2/show/NCT04161885

Jan 14th, 2022 - The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when given as mai...

Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04867928

Jan 14th, 2022 - This is a phase 2, non-randomized, interventional, open-label, multicenter trial evaluating the efficacy of VEN-AZA as a bridge-to-transplant therapy in chemotherapy-treated adult NPM1mut AML patients who experience molecular relapse or progressio...

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine in Patients With Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT03041688

Jan 13th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the toxicities of navtemadlin (KRT-232 [AMG-232]) in combination with decitabine (20 mg/m^2 for 10 days), and to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of KRT-232 (AMG-232) in c...

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) (MK-0482-002)
https://clinicaltrials.gov/ct2/show/NCT05038800

Jan 13th, 2022 - The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and recommended Phase 2 dose (RP2D) of MK-0482. There are 2 parts of this study. Part 1 is a dose escalation which will follow an accelerated ti...

see more →

News  1,055 results

Aspacytarabine Shows Efficacy, Safety in Newly Diagnosed AML Unfit for Intensive Therapy
https://www.onclive.com/view/aspacytarabine-shows-efficacy-safety-in-newly-diagnosed-aml-unfit-for-intensive-therapy

Jan 10th, 2022 - The novel antimetabolite aspacytarabine (BST-236) was found to produce a complete remission (CR) rate of 37% in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive therapy, according to data from a phase 2b...

Cilta-Cel Continues to Impress With Durable and Deep Responses in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/cilta-cel-continues-to-impress-with-durable-and-deep-responses-in-relapsed-refractory-multiple-myeloma

Jan 4th, 2022 - Ciltacabtagene autoleucel (cilta-cel) elicited a 97.9% objective response rate (ORR) and an 82.5% stringent complete response (sCR) rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up, accor...

APVO436 Demonstrates Manageable Safety With Anti-Neoplastic Activity in Relapsed/Refractory AML/MDS
https://www.onclive.com/view/apvo436-demonstrates-manageable-safety-with-anti-neoplastic-activity-in-relapsed-refractory-aml-mds

Jan 4th, 2022 - The investigational bispecific antibody APVO436 demonstrated tolerability with encouraging anti-neoplastic efficacy in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), according to updated findings ...

Penson Provides a Snapshot View of Switch Maintenance Therapy Selection in Recurrent Ovarian Cancer
https://www.onclive.com/view/penson-provides-a-snapshot-view-of-switch-maintenance-therapy-selection-in-recurrent-ovarian-cancer

Jan 4th, 2022 - Switch maintenance therapy with bevacizumab (Avastin) or PARP inhibitors, such as olaparib (Lynparza), niraparib (Zejula), or rucaparib (Rubraca), has improved outcomes for patients with platinum-sensitive recurrent ovarian cancer, said Richard Pe...

Innovative Center Focuses on Phase I Trials
https://www.onclive.com/view/innovative-center-focuses-on-phase-i-trials

Jan 3rd, 2022 - Angela Alistar, MD Medical Director Gastrointestinal Medical Oncology Morristown Medical Center A partnership between a healthcare system in Morristown, New Jersey, and a genomics research institute in Phoenix, Arizona, has led to the ope...

see more →

Patient Education  4 results see all →